Summit Therapeutics (NASDAQ: SMMT) director receives option grants

Rhea-AI Filing Summary

Summit Therapeutics Inc. reported that director Kenneth A. Clark received new stock option awards. On January 2, 2026, he was granted 35,000 stock options with an exercise price of $17.52 per share, vesting in four quarterly installments during the year of grant, as long as he continues serving as a non-salaried director on each vesting date. On the same date, he also received a separate grant of 17,796 stock options with the same exercise price, issued under the company’s Director Retainer Option Election Plan in lieu of $155,900 of cash retainer fees. All reported options are held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clark Kenneth A

(Last) (First) (Middle)

C/O SUMMIT THERAPEUTICS INC.

601 BRICKELL KEY DRIVE, SUITE 1000

(Street)

MIAMI FL 33131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc. [ SMMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$17.52	01/02/2026		A		35,000		(1)	01/02/2036	Common Stock	35,000	(2)	35,000	D
Stock Option (right to buy)	$17.52	01/02/2026		A		17,796		(3)	01/02/2036	Common Stock	17,796	$8.76(4)	17,796	D

Explanation of Responses:

1. The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date.

2. Not applicable.

3. The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date.

4. The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $155,900.

Remarks:

	/s/ Bhaskar Anand, as Attorney-in-Fact for Kenneth Clark	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Summit Therapeutics (SMMT) report for Kenneth A. Clark?

The company reported that director Kenneth A. Clark received two grants of stock options on January 2, 2026, totaling 52,796 options to buy Summit Therapeutics common stock.

How many Summit Therapeutics (SMMT) options were granted and at what exercise price?

Kenneth A. Clark was granted 35,000 stock options and a separate grant of 17,796 stock options, each with an exercise price of $17.52 per share.

How do the new Summit Therapeutics (SMMT) options for Kenneth A. Clark vest?

For each grant, the options vest in four quarterly installments on March 31, June 30, September 30 and December 31, subject to Clark remaining a non-salaried director on each vesting date.

Why did Summit Therapeutics (SMMT) issue 17,796 options to Kenneth A. Clark?

The 17,796 stock options were issued under the issuer's Director Retainer Option Election Plan in lieu of $155,900 in director retainer fees.

Are Kenneth A. Clark’s Summit Therapeutics (SMMT) options held directly or indirectly?

The Form 4 shows that the 35,000 and 17,796 stock options are held directly by Kenneth A. Clark.

What role does Kenneth A. Clark have at Summit Therapeutics (SMMT)?

According to the filing, Kenneth A. Clark is a director of Summit Therapeutics Inc. and is not listed as an officer or 10% owner.